Wockhardt

May 28 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT - INDIAN DRUG REGULATOR GRANTS MARKETING AUTHORIZATION TO WOCKHARDT'S ZAYNICH FOR COMPLICATED URINARY TRACT INFECTIONS

Source text: ID:nBSE7q58z2

Further company coverage: WCKH.NS

(([email protected];))

** Shares of India's Wockhardt WCKH.NS rise 10.5% to 1575 rupees, their highest since September 29, 2025

** Drugmaker reports fourth-quarter consolidated net PAT of 1.66 billion Indian rupees ($16.78 million) vs loss a year ago

** Fourth-quarter revenue up about 30% Y/Y

** The stock is up 8.5% YTD

($1 = 95.3675 Indian rupees)

(Reporting by Brijesh Patel in Bengaluru)

(([email protected]; Ph no. +91 9590227221;))

May 4 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT LTD - APPROVED ENABLING PROPOSAL FOR FUND RAISING VIA EQUITY OR SECURITIES

Source text: ID:nNSE25T3Vn

Further company coverage: WCKH.NS

(([email protected];))

March 30 (Reuters) - Wockhardt Ltd WCKH.NS:

• ZAYNICH RECEIVES FAVOURABLE RECOMMENDATION FROM CDSCO SUBJECT EXPERT COMMITTEE

Source text: ID:nNSE1WsNq

Further company coverage: WCKH.NS

(([email protected];))

Feb 10 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT LTD DEC-QUARTER CONSOL NET PAT 590 MILLION RUPEES

• WOCKHARDT LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 8.88 BILLION RUPEES

Source text: ID:nBSE7y9x4V

Further company coverage: WCKH.NS

(([email protected];))

Jan 27 (Reuters) - Wockhardt Ltd WCKH.NS:

• FOVISCU® MEETS MAIN GOAL IN PHASE 3 TRIAL

Source text: ID:nBSE9QYxcm

Further company coverage: WCKH.NS

(([email protected];))

Jan 7 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT - FILES MARKETING AUTHORISATION APPLICATION FOR WCK 5222 WITH EUROPEAN MEDICINES AGENCY

Source text: ID:nNSE6RwJ76

Further company coverage: WCKH.NS

(([email protected];;))

** Shares of India's Wockhardt WCKH.NS rise 4.6% to 1438 rupees

** Drugmaker says European Medicines Agency clears co's medication targeting drug-resistant infections for accelerated assessment

** Stock up 1.8% YTD, set for slowest annual gains in three years

(Reporting by Abhirami G in Bengaluru)

(([email protected]))

** India's Nifty Pharma sub-index .NIPHARM rises 0.8%

** U.S. Senate passes 2026 National Defense Authorization Act, which includes "Biosecure Act" that bars some Chinese biotech companies from receiving federal funding

** Citi says latest version doesn't name specific firms, but defense department indicated a major Contract Development and Manufacturing Organization (CDMO) might be effected

** Brokerage adds risk likely to keep global pharma innovators focused on supply chain diversification, potentially benefiting Indian CDMOs, especially Divi's Laboratories DIVI.NS

** DIVI up as much as 3.4%

** Wockhardt WCKH.NS biggest pct gainer, rising 4.7%, followed by Laurus Labs's LAUL.NS 2.9% advance

** YTD, DIVI up 7% vs NIFTYPHARM's ~3% drop

(Reporting by Urvi Dugar in Bengaluru)

(([email protected];))

Sept 10 (Reuters) - Shukra Pharmaceuticals Ltd SHUR.BO:

• AUTHORIZED BY WOCKHARDT FOR PAN INDIA DISTRIBUTION

• NON-EXCLUSIVE AUTHORIZATION VALID TILL MARCH 2026

Source text: ID:nBSE6r6rxb

Further company coverage: SHUR.BO

(([email protected];;))

Aug 8 (Reuters) - Wockhardt Ltd WCKH.NS:

• JUNE-QUARTER CONSOL NET LOSS AFTER TAX 900 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 7.38 BILLION RUPEES

Source text: ID:nBSE3KGzst

Further company coverage: WCKH.NS

(([email protected];;))

** Shares of Wockhardt WCKH.NS rise 4.4% to 1,829.5 rupees, their highest in over 3 weeks

** Pharma co plans to shut down its loss-making US generic pharmaceutical segment in 15 months

** The shutdown is part of its US ops' realignment to focus on two segments - new antibiotic drug discovery, and biologicals portfolio in insulin

** Stock up 27.6% YTD

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

July 11 (Reuters) - Wockhardt Ltd WCKH.NS:

• TAKEN DECISION TO EXIT US GENERIC PHARMACEUTICAL SEGMENT

• INITIATES STRATEGIC REALIGNMENT OF US OPERATIONS TO FOCUS ON INNOVATIVE PORTFOLIO

• FILED VOLUNTARY LIQUIDATION OF MORTON GROVE PHARMACEUTICALS INC, WOCKHARDT USA LLC

Source text: [ID:]

Further company coverage: WCKH.NS

(([email protected];;))

** India's Senores Pharma SENO.NS rises 3% to 517.70 rupees

** Drugmaker says it acquired generic version of hypertension drug Enalapril Maleate from Wockhardt WCKH.NS

** Market size for the drug is estimated at $109.2 mln in US, says SENO citing data aggregator Symphony

** Adds, co will fund acquisition for the drug via proceeds it raised during its IPO in December 2024

** Stock down 7% since its trading debut

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of India's Wockhardt Ltd WCKH.NS rise as much as 3.9% to 1,442 rupees

** Pharma co says its antibiotic drug Zaynich, which targets multi-drug-resistant, gram-negative infections, achieved over 97% efficacy in clinical study for serious infections

** Stock on track to snap three days of losses

** WCKH gained 233.9% in 2024, its second straight year of gains

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

** Shares of pharma co Wockhardt WCKH.NS rise as much as 9.4% to highest since Dec. 2015 to 1,582.95 rupees

** Co on Thursday said Indian drug regulator approved co's antibiotic drug Miqnaf for treatment of pneumonia

** WCKH shares on track for fourth straight week of gains

** WCKH shares jumped more than three-fold last year vs 39% gains in pharma index .NIPHARM

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

Jan 2 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT LTD - INDIAN DRUG REGULATOR APPROVES WOCKHARDT'S ANTIBIOTIC MIQNAF

Source text: ID:nBSE68Xcxt

Further company coverage: WCKH.NS

(([email protected];))

Dec 16 (Reuters) - Wockhardt Ltd WCKH.NS:

• ZAYNICH ENABLES SUCCESSFUL LIVER TRANSPLANT FOR US CANCER PATIENT

Source text: ID:nBSE2ctvdc

Further company coverage: WCKH.NS

(([email protected];;))

** Wockhardt WCKH.NS climbs ~2.5% to 1,210 rupees

** Pharmaceutical co's Q2 consol net loss narrows to 220 mln rupees ($2.6 mln) from year-ago loss of 770 mln rupees

** Revenue up 7.4%; expenses largely flat

** WCKH was down ~3% ahead of the results

** Stock has nearly tripled in 2024

($1 = 84.3700 Indian rupees)

(Reporting by Nishit Navin)

(([email protected];))

** Wockhardt WCKH.NS rises 5%, hitting the upper limit of exchange-allowed trading band, to 1,208.35 rupees

** About 349,616 shares traded in five block deals at a premium of 3.8%-5% to last close - LSEG

** Overall 1.02 mln shares traded, 3x the 30-day average

** WCKH up ~185% YTD

(Reporting by Vijay Malkar)

(([email protected];))

Oct 16 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT FILES FAST-ACTING INSULIN ASPART INJECTION WITH DCGI

Source text for Eikon: ID:nBSE4ynTbf

Further company coverage: WCKH.NS

(([email protected];))

Oct 11 (Reuters) - Wockhardt Ltd WCKH.NS:

• NAFITHROMYCIN GETS FAVOURABLE RECOMMENDATION FROM CDSCO

Source text for Eikon: ID:nNSE5QlT87

Further company coverage: WCKH.NS

(([email protected];;))

Oct 7 (Reuters) - Wockhardt Ltd WCKH.NS:

• WOCKHARDT LTD - WCK 6777 GRANTED FAST TRACK DESIGNATION BY US FDA, COMPLETES PHASE I STUDY

Source text for Eikon: ID:nBSE3D2wSM

Further company coverage: WCKH.NS

(([email protected];))

** Shares of Wockhardt Ltd WCKH.NS rise as much as 5% to 1,005.70 rupees

** Pharma co says its investigational drug Zaynich cures complex case of meningitis in a 64-year-old patient

** Co says drug has treated over 35 critically ill patients in India and US in the past year

** Stock on track to snap 3 days of losses

** More than 232,000 shares traded as of 1:36 p.m. IST, busiest day in more than a week

** Stock gained 137% YTD

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

Sept 6 (Reuters) - Wockhardt Ltd WCKH.NS:

• CLARIFIES ON ALLEGATIONS PERTAINING TO PAYMENT OF RENT BY CAROL INFO SERVICES

• CATEGORICALLY DENY ALLEGATIONS

• THESE ALLEGATIONS ARE COMPLETELY "BASELESS AND MISLEADING"

Source text for Eikon: ID:nBSE8MPBKc

Further company coverage: WCKH.NS

(([email protected];;))

** Shares of pharmaceuticals company Wockhardt WCKH.NS rise 3.5% to 990 rupees

** Stock on track for fourth straight session of gains

** Co reports narrower Q1 loss of 140 mln rupees ($1.7 mln) from loss of 1.34 bln rupees year ago, helped by new launches

** Larger rival Sun Pharmaceutical SUN.NS beat Q1 profit estimates earlier this month

** WCKH up 130% YTD, while Nifty Pharma index .NIPHARM which includes SUN and WCKH's other peers, is up by around 32%

** WCKH is not part of the Pharma index

($1 = 83.9340 Indian rupees)

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

Aug 9 (Reuters) - Wockhardt Ltd WCKH.NS:

• JUNE-QUARTER CONSOL NET LOSS AFTER TAX 140 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 7.39 BILLION RUPEES

Source text for Eikon: ID:nBSE9DDsS3

Further company coverage: WCKH.NS

(([email protected];))

** Shares of pharma and biotech co Wockhardt WCKH.NS rise as much as 12% to 943 rupees, highest since August 5, 2016

** Stock on track for an eleventh consecutive session of gain, if trends hold

** On Monday, WCKH's shares rose an exchange-allowed maximum of 20% after its antibiotic drug Zaynich successfully treated a cancer patient in the U.S.

** Share price above 50-day, 100-day and 200-day exponential moving averages since June 19

** Trading vol 2.9x 30-day daily avg

** Stock rose 17.2% in June quarter, its third straight quarterly rise

** Stock last up 6.7%, pushing YTD gains to 111.5%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

** Shares of pharma and biotech co Wockhardt WCKH.NS rise an exchange-allowed maximum of 20% to 823.9 rupees

** Co said its antibiotic drug Zaynich successfully treated a cancer patient in the U.S. with chronic bilateral thigh infection

** The U.S. Clinical and Laboratory Standards Institutes (CLSI) grants high susceptibility breakpoint to the drug on its success

** Susceptibility breakpoint is a key metric for doctors to recognize most effective antibiotics

** Stock eyes busiest trading session since mid-Feb, over 5.5 mln shares traded

** Including session's gains, stock up ~94% YTD

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))